Pd nanoparticles fabricated cyano-functionalized mesoporous SBA-15: A novel heterogeneous catalyst for Suzuki–Miyaura coupling reactions and anti-human lung cancer effects

• Published in: Materials chemistry and physics Vol. 257; p. 123375
• Main Authors: Wang, Junling, Wang, Linlin, Cai, Xiaoping, Karmakar, Bikash, Zangeneh, Mohammad Mahdi, Liu, Hairong
• Format: Journal Article
• Language: English
• Published: Lausanne Elsevier B.V 01.01.2021; Elsevier BV
• Subjects: Atomic beam spectroscopy; Biotechnology; Catalysts; Catalytic activity; Chemical reactions; Chemotherapeutic drug; Coupling; Covalent bonds; Electron microscopy; Emission analysis; Field emission microscopy; Human lung cancer; Inductively coupled plasma; Inert atmospheres; Lung cancer; Microscopy; Nanoparticles; Photoelectrons; Reaction time; Room temperature; SBA-15; Spectrum analysis; Suzuki-miyaura coupling; Toxicity; X ray photoelectron spectroscopy; X-ray spectroscopy; Pd; Chemotherapeutic drug; SBA-15; Human lung cancer; Suzuki-miyaura coupling
• ISSN: 0254-0584; 1879-3312
• DOI: 10.1016/j.matchemphys.2020.123375

A novel Pd (0) nanoparticles anchored over cyano modified SBA-15 was synthesized and characterized with different physicochemical techniques like Transmission Electron Microscopy (TEM), Field Emission Scanning Electron Microscopy (FESEM), Energy Dispersive X-ray Spectroscopy (EDX), N2 adsorption-desorption isotherm, X-ray elemental mapping and X-ray Photoelectron Spectroscopy (XPS). Pd content on the catalyst surface was determined to be 0.12 mmol/g by induced coupled plasma atomic emission spectroscopy (ICP-AES). The composite surface material was described as a novel heterogeneous nanocatalyst for the ligand-free C–C bond formation using Suzuki-Miyaura coupling at room temperature in air without the use of inert atmosphere. It afforded excellent yields in short reaction time. The catalyst was recovered and recycled 12 times without a significant loss of catalytic activity. To survey the cytotoxicity and anti-human lung cancer properties of catalyst, MTT assay was used on the common human lung cancer cell lines i.e., moderately differentiated adenocarcinoma of lung (LC-2/ad), poorly differentiated adenocarcinoma of lung (PC-14), and well-differentiated bronchogenic adenocarcinoma (HLC-1). The catalyst had high anti-human lung cancer and very low cell viability potentials dose-dependently against LC-2/ad, PC-14, and HLC-1 cell lines. The best result of anti-human lung cancer effects was observed in the case of the PC-14 cell line. After approving the above results in the clinical trial studies, catalyst may be used as a chemotherapeutic drug for the treatment of human lung cancer. [Display omitted] •A Pd (0) NPs anchored modified mesoporous SBA-15 novel heterogeneous catalyst is synthesized.•The catalytic activity explored in the synthesis of biaryls by Suzuki-Miyaura coupling.•The nanocatalyst could be recovered several times without significant loss of its catalytic activity.•The catalyst had high anti-human lung cancer.